Topical 5-Fluorouracil Effervescent Powder in the Treatment of Vitiligo
Development and Clinical Evaluation of Topical 5-Fluorouracil Effervescent Powder Formulation in the Treatment of Vitiligo
Al-Azhar University
60 participants
Oct 15, 2022
INTERVENTIONAL
Conditions
Summary
A novel approach for 5-Fluorouracil delivery based on a solid effervescent formulation is proposed . 5-Fluorouracil is water soluble (\~50mg/ml) and therefore has been used for the development of novel topical formulations including nano and microparticles intended for skin targeting. After hydration 5-Fluorouracil could form a complex, a suspension or even be formulated to generate effervescence. In effervescent technology, gas bubbles occur from the liquid after chemical reaction between alkali salts and organic acids (mainly citric or tartaric. Due to liberation in CO2 gas, the dissolution of drug in water is enhanced. The aim of this study is the development and clinical evaluation of topical 5-florouracil effervescent powder formulation in the treatment of vitiligo.
Eligibility
Inclusion Criteria5
- Patients who will be diagnosed as localized stable vitiligo.
- Age older than 10 years
- Stability of lesions for a duration of at least 1 year.
- Patients who didn't receive treatment for vitiligo in the previous 6 weeks before starting the study.
- Patients who agreed to join the study and signed written consent and continued till the end of the follow up period
Exclusion Criteria4
- Patients with vitiligo patches on mucous membrane,
- Patients with Koebner phenomenon,
- Other uncontrolled systemic illnesses
- Patients receiving any systemic or topical treatment for vitiligo
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
30 patients will apply a new effervescent mixture 5-florouracil formula prepared at faculty of pharmacy (Girls) - Al-Azhar university
30 patients will apply the 5-florouracil plain powder on the selected patch followed by 3 milliliters of water till complete dissolution of the powder
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05536856